ArticleFrontiers in public health2022
Emergence of Hypervirulent ST11-K64
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Definitional ambiguity and the dual threat of Hypervirulent Klebsiella pneumoniae infections: a systematic review and meta-analysis.Infection · 2026Pooled it
- Systematic review and meta-analysis on the carbapenem-resistant hypervirulent Klebsiella pneumoniae isolates.BMC pharmacology & toxicology · 2025Pooled it
- Mortality risk of carbapenem-resistant hypervirulentFrontiers in public health · 2025Pooled it
- Molecular Insights Into Hypervirulent Klebsiella pneumoniae: Identification and Correlation of Virulence Determinant.MicrobiologyOpen · 2026Article
- Increased virulence and decreased antimicrobial resistance in Klebsiella pneumoniae in Beijing since 2020: a retrospective molecular epidemiology study.Science China. Life sciences · 2026Article
- Deciphering the Genetic Mechanisms Driving Carbapenem Resistance: A Multicenter Study from Seven Egyptian Governorates Using Multiplex PCR and Whole Genome Sequencing.Current microbiology · 2026Article
- Genome-Wide Association of ST, K-, and O-Locus Diversity with Virulence in Indian Klebsiella pneumoniae via Targeted Phenotypic Validation.Current microbiology · 2026Article
- Comparative Proteomic Profiling of ClinicalJournal of extracellular biology · 2026Article
- The acquisition ofmBio · 2026Article
- Co-evolution of resistance and virulence inFrontiers in cellular and infection microbiology · 2026Review
- Phenotypic and molecular characterization of K64 putative hypervirulent carbapenem-resistant Klebsiella pneumoniae.PloS one · 2026Article
- Phenotypic characteristics and plasmid structure differences between ST11 carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- The acquisition ofbioRxiv : the preprint server for biology · 2025Article
- Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review.Microorganisms · 2025Review
- Emergence of ST11-KL64 carbapenem-resistant hypervirulent Klebsiella Pneumoniae isolates harboring blaBMC infectious diseases · 2025Article
- Prevalence, Risk Factors, and Clinical Outcomes of HypervirulentIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- Emergence and clinical challenges of ST11-K64 carbapenem-resistant Klebsiella pneumoniae: molecular insights and implications for antimicrobial resistance and virulence in Southwest China.BMC infectious diseases · 2025Article
- Epidemiological and characteristic differences of hypervirulent and classicalFrontiers in cellular and infection microbiology · 2025Article
- Molecular Characterization and Risk Factors of Carbapenem-Resistant HypervirulentInfection and drug resistance · 2025Article
- In vitro Evaluation of the Antibacterial Activity of the Combination of Avibactam and β-Lactams Against Highly Virulent Carbapenem-ResistantInfection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The carbapenem-resistant hypervirulent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.